Where the blockbuster weight loss drug market stands today — and what's coming next

The GLP-1 market for weight loss and diabetes is rapidly expanding towards a projected $100 billion by 2030, with Eli Lilly currently dominating market share due to superior drug efficacy and tolerability. Novo Nordisk, however, faces significant challenges including stock underperformance, lowered forecasts, impending Medicare price negotiations for its key semaglutide products, and persistent competition from compounded versions. The future landscape will be shaped by evolving insurance coverage, the introduction of more convenient oral medications with varying efficacy profiles, and the emergence of next-generation drugs from a competitive field of biotechs and pharma giants.

Analysis

Eli Lilly (LLY) has significantly strengthened its market leadership in the GLP-1 sector, now accounting for nearly 60% of injectable obesity and diabetes prescriptions and consistently gaining share for five consecutive quarters. This dominance is attributed to the superior efficacy and tolerability of its drugs, Mounjaro and Zepbound, compared to Novo Nordisk's (NVO) offerings. Novo Nordisk, conversely, has experienced a nearly 40% stock decline this year, lowered profit forecasts, and faces competitive pressures from Eli Lilly's superior products and persistent compounded versions.

Novo Nordisk's challenges extend to regulatory and strategic fronts, with its semaglutide products facing Medicare price negotiations effective 2027, a risk Eli Lilly's tirzepatide largely avoids until later in the decade. The company has responded with a significant restructuring, including a new CEO and a 11.5% workforce reduction, indicating a critical period of strategic adjustment. The ongoing issue of compounded GLP-1s, predominantly semaglutide, continues to impact NVO's market share despite legal efforts and increased manufacturing capacity.

The future market trajectory will be shaped by the expansion of insurance coverage, which remains a key barrier due to high treatment costs, although employer coverage is gradually increasing. The anticipated introduction of oral GLP-1s, with Eli Lilly's orforglipron projected to capture a substantial share of this segment due to its small-molecule advantages and manufacturing scalability, could significantly broaden market access by appealing to needle-averse patients. However, the ultimate adoption will depend on their efficacy and competitive pricing relative to existing injections.

Beyond current treatments, the industry is actively exploring new indications for GLP-1s, such as Alzheimer's, and developing next-generation therapies like amylin analogs and less frequent injections from companies like Amgen. These innovations promise further market expansion, but their success will hinge on demonstrating clear differentiation in efficacy, tolerability, and scalable production, particularly for smaller biotechs seeking strategic partnerships with larger pharmaceutical firms.

Key Decisions for Investors

• Investors should re-evaluate Novo Nordisk (NVO) positions given its significant market share erosion, competitive disadvantages in efficacy and tolerability, and impending regulatory and pricing pressures from Medicare.
• Consider maintaining or increasing exposure to Eli Lilly (LLY) due to its established market dominance, superior product efficacy, and favorable positioning regarding future oral therapies and regulatory pricing.
• Monitor the development and market penetration of oral GLP-1s, particularly Eli Lilly's orforglipron, as these could expand the total addressable market and shift competitive dynamics.
• Assess the evolving landscape of insurance coverage and the impact of new indications and next-generation therapies on long-term market growth and individual company valuations.